Eurofins Transplant Genomics and Viracor Will Partner to Offer Remote Sample Collection Options to Support Care for Kidney Transplant Recipients During COVID-19 Outbreak

MANSFIELD, Mass., March 18, 2020 /PRNewswire/ -- Transplant Genomics, Inc. ("TGI"), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics, today announced that it has partnered with sister Eurofins company Eurofins Viracor, and established relationships with Quest and various mobile sample collection groups, to enable patients to have samples collected remotely for analysis with our unique catalog of tests critical to monitoring health of kidney transplant recipients without requiring them to visit transplant centers.

Key testing services include:

- TruGraf: the only blood test approved by CMS for surveillance to rule out silent rejection in stable kidney transplant recipients and provide comfort that patients are likely to be immune quiescent (via Transplant Genomics)

- TRAC: to analyze donor-derived cell-free-DNA levels in blood to rule out rejection in patients suspected of rejecting (via Viracor)

In addition, Eurofins Viracor is now offering testing for SARS-CoV-2 in kidney transplant donors and recipients.  Please contact us for details concerning how we can help you provide your patients with access to this important test.

Eurofins is committed to supporting physicians in providing optimal care for their transplant patients.  With the outbreak of COVID-19, we understand that transplant programs are minimizing office visits, both to ensure patient health and safety, as well as reduce the burden on staff so they may focus their care on patients who are most in need.  By offering our unique catalog of tests, and making available remote sample collection options, we are doing our part to support patient care during this difficult time.

For information on ordering tests and arranging remote sample collection, physicians may contact us directly at 1-844-TruGraf or (800) 305-5198 for Eurofins Viracor Client Services.  You may also visit our websites at www.trugraf.com, Viracor-Eurofins.com/TRAC and Viracor-Eurofins.com/Coronavirus.

About Transplant Genomics, Inc.
Transplant Genomics, Inc. ("TGI") is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immune-suppressive therapy, enhance patient care and improve graft survival. Test services are offered through TGI's CLIA laboratory in Pleasanton, CA.  TGI was acquired by Eurofins in 2019.

Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is a scientific leader in food, environment, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.

SOURCE Eurofins Transplant Genomics

Related Links

http://www.viracor-eurofins.com